ERIN WOFFORD: Open Payments
NPI 1093394546 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,594 in 115 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $214 · 2025 $1,594
Food & beverage: $1,594
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $355 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $261 |
| Novo Nordisk Inc | 16 | $196 |
| PFIZER INC. | 11 | $167 |
| Lilly USA, LLC | 14 | $164 |
| GlaxoSmithKline, LLC. | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 5 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
Products named: CAPLYTA, UBRELVY, VRAYLAR, PREVNAR 20, MOUNJARO, Wegovy, REXULTI, Ozempic.
Industry payments across KY — which companies pay providers there.
